You might also like
MAIA Biotechnology, Inc. is a biopharmaceutical company focused on developing oncology drug candidates to improve and extend the lives of people with cancer. The company specializes in targeted therapy and immuno-oncology, with a primary focus on telomere-targeting agents for cancer treatment. Its flagship product is THIO, a first-in-class cancer telomere-targeting agent currently in clinical development for non-small cell lung cancer (NSCLC) patients with telomerase-positive cancer cells.
- THIO (6-thio-dG) - A first-in-class cancer telomere-targeting agent in clinical development for treating NSCLC patients with telomerase-positive cancer cells. Telomerase is present in over 85% of cancers, making THIO a critical innovation in oncology.
- Next-Generation Telomere-Targeting Agents - A pipeline of 84 new molecules with the same mechanism of action as THIO, expected to follow THIO to the commercial stage within 4-5 years.
- Clinical Trials - Includes THIO-101 for NSCLC, THIO-102 for colorectal cancer (CRC), hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), and soft tissue tumors, and THIO-103 for NSCLC and SCLC.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Vlad Vitoc ExecutiveBoard | Chief Executive Officer | Vlad Vitoc is the Chief Executive Officer, Chairman of the Board, and President of MAIA Biotechnology, Inc., holding these roles since September 2018. He brings over 24 years of experience in the pharmaceutical and biotechnology industries, having led strategic initiatives and oncology pipeline developments. | View Report → | |
Jeffrey Himmelreich Executive | Head of Finance and Principal Financial and Accounting Officer | Jeffrey Himmelreich is an experienced financial executive who has served as Head of Finance and Principal Financial and Accounting Officer at MAIA Biotechnology since November 2023, and previously served as Director of Accounting and Financial Reporting from September 2023 to November 2023. | ||
Sergei M. Gryaznov Executive | Chief Scientific Officer | Sergei M. Gryaznov is the Chief Scientific Officer at MAIA Biotechnology, Inc. since December 2019. He is a recognized scientist in oncology and telomere research and previously served as Senior Director Head at Janssen Biopharma from May 2015 to October 2019. | ||
Cristian Luput Board | Director | Founder and CEO of Optimus Realty Inc; Board Member of several charitable organizations | Cristian Luput serves as a Director at MAIA Biotechnology, leveraging his extensive management and entrepreneurial experience. He is also the founder and CEO of Optimus Realty Inc since 2005, along with serving as a board member for several charitable organizations. | |
Jean-Manassé Theagéne Board | Director | CEO of 360Medlink; Strategic Advisor | Jean-Manassé Théagène is a Director at MAIA Biotechnology, Inc., elected to the Board on March 17, 2023 with a term lasting until the 2025 annual meeting. He is also the founder and CEO of 360Medlink since November 2010, bringing over 20 years of life sciences experience. | |
Louie Ngar Yee Board | Director | Louie Ngar Yee serves as a Director on the Board of Directors of MAIA Biotechnology, Inc. since April 2020. She previously served as the Group Chief Operating Officer of Group Internal Audit at HSBC Group from January 2017 to March 2020. | ||
Ramiro Guerrero Board | Director | Founder and CEO of IMPERIO, Inc. | Ramiro Guerrero serves as a Director at MAIA Biotechnology since March 24, 2023. He is also the Founder and CEO of IMPERIO, Inc. since March 2015, with extensive experience in real estate investment, brokerage, and venture capital. | |
Stan V. Smith Board | Director | President, Smith Economics Group, Ltd.; Adjunct Professor at University of Chicago; Adjunct Professor at DePaul University College of Law | Stan V. Smith has served as a Director at MAIA Biotechnology, Inc. since at least March 21, 2024 and is nominated for re-election as a Class III director for a term expiring at the 2026 annual meeting. He brings extensive expertise in economics, financing, and litigation economics to the board. | |
Steven Chaouki Board | Director | President, U.S. Markets & Consumer Interactive at TransUnion | Steven Chaouki is currently serving as Director at MAIA Biotechnology, Inc., as evidenced by filings dated April 19, 2023 and April 21, 2023. He has extensive management experience, including serving as President, U.S. Markets & Consumer Interactive at TransUnion since 2008. |
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Current competitors in the non-small lung cancer indication include this company, which is part of a competitive landscape involving both large and small companies developing products for this indication. Key product features such as efficacy, safety, convenience, and pricing will affect the ability to compete effectively. | |
This company is identified as a competitor in the non-small lung cancer indication and is also the manufacturer of cemiplimab, an immune checkpoint inhibitor used in combination with THIO in clinical trials. | |
This company is listed among the current competitors in the non-small lung cancer indication, highlighting the competitive nature of the biotechnology and pharmaceutical industries. | |
Roche | This company is noted as a competitor in the non-small lung cancer indication, emphasizing the significant competition in developing therapies for this condition. |
Recent press releases and 8-K filings for MAIA.
- CEO Vlad Vitoc outlines the 2025 clinical milestones in the Shareholder Letter, emphasizing MAIA’s lead candidate THIO (ateganosine) as the sole clinical-stage telomere-targeting anticancer agent.
- The letter details a Phase 2 trial expansion for THIO-101 with potential accelerated approval filing and a Phase 3 trial for THIO-104 set to begin mid-2025 with regulatory actions anticipated in 2026.
- MAIA Biotechnology, Inc. filed a Form 8-K on March 28, 2025, reporting the release of efficacy data from its Phase 2 THIO-101 clinical trial in combination with the immune checkpoint inhibitor cemiplimab for advanced NSCLC.
- The efficacy data was presented as a poster at the European Lung Cancer Congress 2025 and is now available on the company’s website as Exhibit 99.1.
- On March 26, 2025, the company decreased its maximum aggregate offering price for common stock from $30,000,000 to $11,200,000 under its ATM offering agreement with H.C. Wainwright.
- The company previously realized approximately $6.29 million in sales and a total of $11.63 million in sales under the offering agreement over the past 12 months.
- A legal opinion confirmed that the shares, once delivered and paid for per the offering agreement, would be validly issued, fully paid, and non-assessable.
- USAN Council approved the nonproprietary name "ateganosine" for MAIA's anticancer agent THIO, marking a key step in its regulatory pathway.
- The approval supports MAIA's advancement into Phase 2 and 3 clinical trials for the treatment of advanced non-small cell lung cancer.
- The announcement was made via an 8‑K press release on March 19, 2025, indicating progress in the company's clinical development strategy.
- MAIA Biotechnology has initiated a non-brokered private placement to raise approximately $1.43 million by issuing 952,300 shares of common stock at $1.50 per share, with each share accompanied by a warrant to purchase one additional share at $1.85 per share.
- The offering is expected to close on or about February 26, 2025 and will provide funds to support Part C of the Phase 2 THIO-101 clinical trial and for working capital purposes.
- The overall transaction, when combined with a separate private placement of approximately $2.7 million, will yield aggregate gross proceeds of about $4.1 million prior to expenses.
- MAIA Biotechnology, Inc. announced a private placement of common stock and warrants valued at approximately $2.715M, with shares priced at $1.50 and warrants exercisable at $1.87.
- The offering targets accredited investors and select directors and is intended to fund the startup costs for Part C of the Phase II trial THIO‑101 as well as support working capital.
- The closing of the private placement is expected on or about February 20, 2025.
- Positive clinical trial results from the Phase 2 THIO-101 trial in advanced NSCLC showed a median overall survival of 16.9 months for patients in the third-line setting, significantly exceeding standard-of-care survival of 5–6 months.
- The trial evaluated THIO administered sequentially with Regeneron’s cemiplimab (Libtayo®) in a heavily pre-treated population, bolstering the company’s regulatory strategy for accelerated FDA approval.